

## Prevention & Treatment of Hepatitis and Chronic Liver Disease

**Raleigh-Durham, NC – March 19, 2022**

<b>Conference Location</b>	<b>Embassy Suites - Raleigh Crabtree</b> 4700 Creedmoor Rd Raleigh, NC	<b>Phone: (919) 881-0000</b>  <a href="https://www.hilton.com/en/hotels/rducmes-embassy-suites-raleigh-crabtree">https://www.hilton.com/en/hotels/rducmes-embassy-suites-raleigh-crabtree</a>
----------------------------	--	---

**Parking at the Conference** Complimentary parking has been arranged for all seminar participants.

	<b>From the Raleigh Durham Airport:</b>	
<b>Driving Directions</b>	<ul style="list-style-type: none"> <li>Get on US-70 E/Glenwood Ave in Raleigh from Airport Blvd/John Brantley Blvd, E International Dr and Commerce Blvd</li> <li>Merge onto US-70 E/Glenwood Ave</li> <li>Exit and Turn Left on Creedmoor Road</li> <li>Turn Right at the first cross street (Marriott Drive)</li> <li>The hotel will be on your left</li> </ul>	

**Seminar Agenda and Syllabus Information** Registration begins at **7:00am** in the **Graham-Bell Room**. Please check signage for any last-minute room changes.  
**The Emerging Therapies seminar is a paperless program.** The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.

<b>Pre-Program Activities</b>	<b>Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min <b>Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
<b>7:00am</b>	<b>Registration and View Exhibits</b>
<b>7:30 am</b>	<b>Opening Comments and Pre-Test</b>
<b>7:45 am</b>	<b>Hepatitis C: Update on Diagnostics</b> <ul style="list-style-type: none"> <li>Short recap of key points from Pre-course lecture on viral hepatitis</li> <li>Screening and diagnostic approaches of HCV</li> </ul> <b>Hepatitis C: Update on Treatment</b> <ul style="list-style-type: none"> <li>AASLD/IDSA Guidelines and Updates</li> <li>Simplified Guidance</li> </ul> <b>Case Studies 1 and 2</b> –New Case relevant to diagnosis and treatment of high-risk HCV patient
<b>8:35am</b>	<b>Hepatitis B: Epidemiology, Natural History and Testing</b> <ul style="list-style-type: none"> <li>The epidemiology of the Hepatitis B infection</li> <li>Efficacies and opportunities in HBV testing and vaccination</li> <li>The growing relationship between HBV and HDV</li> </ul>
<b>9:05 am</b>	<b>Anti-viral Therapies for HBV</b> <ul style="list-style-type: none"> <li>Early detection and treatment approaches</li> <li>Treating HCC in patients with Hepatitis B</li> <li>Reactivation of HBV</li> </ul>

9:35 am	<b>Industry Presentation #1 Break and View exhibits</b>
10:15 am	<b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>Worldwide perspective and promising research studies</li> <li>Real world outcome studies on HDV and HEV</li> </ul>
10:45 am	<b>End Stage Liver Disease: Recap and Clinical Case</b> <ul style="list-style-type: none"> <li>A review of Pre-course lecture touching on staging, work-up and remedies for cirrhosis and the liver transplant process</li> </ul>
11:15 am	<b>Alcoholic Liver Disease</b> <ul style="list-style-type: none"> <li>The growing prevalence of alcohol over-consumption and its impact on liver health</li> </ul> Warning signs and intervention in alcoholic hepatitis
11:45 am	<b>Hepatocellular Carcinoma (HCC)</b> <ul style="list-style-type: none"> <li>Screening diagnostic serum assays and imaging tests</li> <li>Treatment and management options: Ablation, TACE and Surgery</li> </ul>
12:15 pm	<b>Luncheon and Industry Presentation #2</b>
1:00pm	<b>Dessert and View Exhibits</b>
1:10 pm	<b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>Current FDA-Approved Therapies</li> <li>New chemotherapy regimens in development and testing</li> <li>Immunotherapy as the new MoA for HCC</li> </ul> <b>Case Study 3– Diagnosis and Treatment of Hepatocellular Carcinoma</b>
1:40 pm	<b>SARS-COV-2 in Liver Disease</b> <ul style="list-style-type: none"> <li>Effect of COVID on the liver and in cirrhotic patients</li> <li>COVID-19 challenges for liver transplant recipients</li> </ul>
2:10pm	<b>Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis</b> <ul style="list-style-type: none"> <li>Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>Predicting outcomes and Improving Survival in PSC patients</li> <li>Causes and Markers of PBC</li> <li>Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> </ul>
2:45 pm	<ul style="list-style-type: none"> <li><b>Break &amp; View Exhibits</b></li> </ul>
3:00 pm	<b>NAFLD and NASH</b> <ul style="list-style-type: none"> <li>Epidemiology, Demographics and Diagnosis</li> <li>Scoring, Staging and Management of Fatty Liver Disease</li> <li>Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul>
3:35 pm	<b>NASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>Current therapies for NASH including Updates from AASLD and EASL</li> <li>Lifestyle changes as a therapy</li> <li>Drugs in clinical development for NASH</li> </ul>
4:25 pm	<b>Closing Comments, Post-test and Wrap-Up</b> Program adjourns at 4:45 pm
Post-program activities	<b>Lecture 3 - Viral Hepatitis Updates: The reemergence of Hepatitis A and Overcoming barriers to liver health in special populations - 60 minutes</b>

---

**Attendance  
Policies**

**Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

**Recording and Photography**

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

**Guest Attendance**

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**CME  
Information**

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)<sup>TM</sup>**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1264. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)<sup>TM</sup> organizations accredited by ACCME.

---

**Your  
Seminar  
Faculty**



**A. SIDNEY BARRITT, IV, MD, MSCR, FACGA**

Sidney Barritt received his medical degree from University of Virginia School of Medicine in Charlottesville after graduating with a BA in History from the University of Virginia. Later, Dr Barritt continued his education studying Epidemiology and receiving a Master's of Science in Clinical Research degree at the Gillings School of Global Public Health, University of North Carolina-Chapel Hill.

Dr. Barritt is certified in Internal Medicine, Gastroenterology and Transplant Hepatology. Clinically, Dr. Barritt is interested in non-alcoholic fatty liver disease and liver transplant outcomes research. He participates in clinical and diagnostic trials and collaborates with research partners in the UNC school of Pharmacy and School of Public Health.



**ANDREW JOSEPH MUIR, MD, MHS, FAASLD, AGAF**

Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. He has particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.

Dr. Muir attended medical school at Duke University. He went on to complete his internal medicine residency and gastroenterology fellowship at Duke, and he also served as chief resident at the Durham Veterans Administration Medical Center. Dr. Muir joined the faculty in the Division of Gastroenterology at Duke in 2000 and assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010



**ELIZABETH K. GOACHER, PA-C**

Elizabeth K Goacher is a Physician Assistant Specialist in Durham, North Carolina. She graduated with honors from Duke University School Of Medicine in 1998. Having more than 19 years of diverse experiences, especially in treating patients with liver and other GI diseases.

She is affiliated with many hospitals including Duke University Hospital, Duke Health Raleigh Hospital, Duke Regional Hospital, and cooperates with other doctors and specialists in medical group Private Diagnostic Clinic.

---